Rezolute, Inc.
RZLTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Rezolute, Inc. focuses on Biotechnology services and products. Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United. The company carries a $372.9M market cap, placing it firmly in the small-cap category. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Market Cap
$372.9M
Beta
0.54
P/E (TTM)
—
P/E (Fwd)
-8.28
EPS (TTM)
$-0.75
EPS (Fwd)
$-0.47
ROE
-59.0%
ROA
-35.3%
Cash
$107.8M
Total Debt
$934,000
Free CF
-$36.4M
52W Change
-59.2%
Annual Financials
Cash vs Debt
Where RZLT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, RZLT finished 9.09% below its 150-day moving average ($4.07) and 3.14% below its 200-day moving average ($3.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RZLT overbought or oversold?
At the October 20, 2026 close, RZLT's RSI(14) was 42.1, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Rezolute, Inc. holds $107.8M in cash against $934K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$36.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -59.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of 0.54 suggests RZLT is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, RZLT has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RZLT.